Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.51 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.51 |
| ▸ | ACKR3 | P25106 | 14/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15436996 | 0.94 | SCD (0.50) | SCDSCD5ACKR3GPR119HSD11B1 | |
| SCHEMBL15436983 | 0.87 | S1PR1 (0.48) | SCDSCD5ACKR3GPR119S1PR1 | |
| SCHEMBL15436968 | 0.86 | SCD (0.40) | SCDSCD5ACKR3GPR119HSD11B1 | |
| SCHEMBL15436984 | 0.85 | SCD (0.48) | SCDSCD5ACKR3GPR119HSD11B1 | |
| SCHEMBL15436977 | 0.85 | GPR119 (0.58) | SCDSCD5GPR119 | |
| SCHEMBL14238800 | 0.83 | SCD (0.47) | SCDSCD5ACKR3GPR119S1PR1 | |
| SCHEMBL15436969 | 0.82 | SCD (0.53) | SCDSCD5ACKR3S1PR1S1PR3 | |
| SCHEMBL15436995 | 0.81 | S1PR1 (0.47) | SCDSCD5GPR119HSD11B1S1PR1 | |
| SCHEMBL15437008 | 0.80 | GPR119 (0.39) | SCDSCD5ACKR3GPR119HSD11B1 | |
| SCHEMBL14990348 | 0.79 | SCD (0.47) | SCDSCD5ACKR3GPR119S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877464-B1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDE DERIVATIVES AND THEIR USE AS GPR119 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-08-24 | — | — | EP | disclosed |
| EP-2877464-B1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDE DERIVATIVES AND THEIR USE AS GPR119 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-08-24 | — | — | EP | disclosed |
| EP-2877464-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDE DERIVATIVES AND THEIR USE AS GPR119 MODULATORS | Boehringer Ingelheim International GmbH (DE) | 2015-06-03 | — | — | EP | disclosed |
| US-8927726-B2 | N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions containing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927726-B2 | N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions containing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927726-B2 | N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions containing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| WO-2014016191-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDE DERIVATIVES AND THEIR USE AS GPR119 MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | WO | disclosed |
| US-20140031369-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031369-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031369-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031369-A1 | N-CYCLOPROPYL-N-PIPERIDINYL-AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF | GPR119, GPR88, CNR1 | SCD 1100/4885SCD5 1057/4885ACKR3 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.